Novel vaccine promising in treatment of genital warts

Baltimore - Phase II study results point to the potential roleof HspE7 as a safe and effective immunotherapeutic agent for the treatmentof genital warts and other HPV-related sexually transmitted diseases, KeertiV. Shah, M.D., said.

Related Videos
Related Content

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023

New Data on Investigational Agent for HS Presented at Annual Meeting

March 18th 2023

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023

New Data on Investigational Agent for HS Presented at Annual Meeting

March 18th 2023

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023

New Data on Investigational Agent for HS Presented at Annual Meeting

March 18th 2023
© 2023 MJH Life Sciences

All rights reserved.